Close Menu

Clear Labs: Jeff Field

Oct 29, 2020

Clear Labs has hired Jeff Field to be its chief commercial officer. He has more than two decades of experience in healthcare and formerly was CCO at IDbyDNA and VP of oncology at Foundation Medicine. At Clear Labs, Field will oversee the continued commercialization of the company's tests including Clear Safety and Clear Dx nationally and internationally.

More Like This

Mar 05, 2021

Quidel: Joseph Wilkins

Quidel has expanded the size of its board of directors from nine to ten members and appointed Joseph Wilkins to the board.

Wilkins is a partner at healthcare consulting firm TRG Healthcare, a limited partner at privately-held venture capital fund Tech Council Ventures, and is an advisor with Touchdown Ventures, a privately held venture capital group. He previously served as senior vice president and chief transformation and innovation officer for Atlantic Health System, an integrated healthcare delivery system, and prior to that he held positions at Quest Diagnostics and Danaher subsidiary Beckman Coulter.

Mar 05, 2021

PierianDx: Lindsay Mateo

PierianDx, which specializes in cancer informatics for diagnostics and targeted therapies, has appointed Lindsay Mateo as chief business officer. Mateo previously served as head of commercial operations and later as vice president and head of life sciences at Tempus. She has also led commercial teams at Navican, an Intermountain Healthcare Company; and Genoptix, now part of NeoGenomics.

Mar 05, 2021

Prometheus Biosciences: Mark Stenhouse

Prometheus Biosciences, a developer of therapeutic and companion diagnostic products for inflammatory bowel disease, has appointed Mark Stenhouse as chief operating officer. Stenhouse previously served as general manager of the screening business at Exact Sciences. He previously spent nearly 30 years at Abbott Laboratories/AbbVie, most recently as vice president of US immunology. He was also vice president and general manager of the gastroenterology franchise, having spent 10 years working in IBD. Stenhouse currently is a member of the board of directors for Phathom Pharmaceuticals.

Mar 04, 2021

Precipio: Ron Andrews

Precipio has announced that Ron Andrews has joined the company's board of directors. In addition to currently serving as CEO of molecular diagnostics firm OncoCyte, Andrews' past experiences include a term as CEO of Roche Molecular, president of the genetic science division at Thermo Fisher Scientific, president of the medical sciences venture at Life Technologies, and CEO of Clarient.

Mar 03, 2021

Omniome: Thomas O'Lenic

Sequencing firm Omniome has appointed Thomas O'Lenic as chief commercial officer. O'Lenic previously held commercial, general manager, and executive leadership positions with Advanced Cell Diagnostics (now part of Bio-Techne); IntegenX (now part of Thermo Fisher Scientific); Molecular Devices (a Danaher company); PerSeptive Biosystems; Millipore; and FreeSlate.

Mar 03, 2021

Geneoscopy: Vince Wong

Geneoscopy has appointed Vince Wong as it chief commercial officer. Wong previously served as VP of sales at Roche Diagnostics. He has also served as VP and general manager of physician office and specialty diagnostics at the firm. 

Mar 03, 2021

Transplant Genomics: Nicholas Grund, John Slaught, Charles Argentine

Transplant Genomics has appointed Nicholas Grund as president, John Slaught as vice president of sales, and Charles Argentine as director of clinical operations.

Grund will be responsible for developing and implementing new strategies to grow Transplant Genomics' existing business, expanding the company's TruGraf portfolio into new organ types, and working with customers, advocates, and payors to establish long-term relationships. He will head company initiatives to increase TruGraf usage in the community-based nephrology market, and will also shepherd the launch of TruGraf Liver in the second half of 2021.

Grund has more than 25 years of commercial leadership experience in the biopharmaceutical industry, including several global executive roles in finance, sales, and marketing. He previously served as chief commercial officer at AMAG Pharmaceuticals, and also spent 13 years at Sanofi, most recently as the leader of the company's rare disease and multiple sclerosis franchises in the Asia Pacific region and Canada. 

Slaught has more than 25 years of commercial team leadership. He most recently served as VP of sales for Optum.

Argentine has more than 15 years of laboratory management experience, primarily in the areas of genetic sequencing and immunology. He most recently served as director of clinical laboratory operations at Roche Sequencing Solutions.

Mar 03, 2021

Arbor Biotechnologies: Mark Angelino

Arbor Biotechnologies has appointed Mark Angelino to its board of directors. Angelino has more than 20 years of expertise in working with numerous pharmaceutical companies, Arbor said. He was the cofounder and chief operating officer of Generation Bio from 2016 until 2021, and has also served as as senior vice president of pharmaceutical sciences and the rare disease franchise head at Bluebird Bio from 2012 until 2016. He also served as senior director of R&D and site head in Cambridge, Massachusetts for Baxter Healthcare from 2010 to 2012. 

Mar 03, 2021

Seven Bridges: David Ledbetter, Neil Martin, Chris Mattman

Seven Bridges has named three members to its newly created strategic advisory board: David Ledbetter, Neil Martin, and Chris Mattman.

Ledbetter is chief clinical officer at Dascena, a former executive VP and chief scientific officer at Geisinger Health System, and a longtime professor of human genetics. Martin, a neurosurgeon, is director of quality and innovation at Pacific Neuroscience Institute Foundation and previously ran the neuroscience institute at Geisinger. Mattman is division manager of the AI, Analytics, and Innovative Development Organization in the IT section of NASA's Jet Propulsion Laboratory, and also director of the information retrieval and data science group at the University of Southern California.

Mar 01, 2021

GA4GH: Susan Fairley

The Global Alliance for Genomics and Health (GA4GH) has named Susan Fairley the group's first-ever chief standards officer. As such, Fairley will oversee standards development work by GA4GH's technical staff and by more than 200 external contributors. Fairley, who will be based at the European Molecular Biology Laboratory's European Bioinformatics Institute in Cambridge, UK, formerly was project lead for EMBL-EBI's International Genome Sample Resource.

Mar 01, 2021

ERS Genomics: Jon Kratochvil

ERS Genomics has appointed Jon Kratochvil as vice president for business development and licensing for North America. Kratochvil previously served as director of business development and licensing at MilliporeSigma, where he was responsible for global development opportunities for the company's gene editing and novel modalities technologies. He has also previously served as business development director for Washington University, and as licensing manager and competitive intelligence analyst for Abbott Laboratories' diagnostics division.

Feb 24, 2021

Ultivue: Mike Sismour, Mark Rees

Ultivue, a company specializing in multiplex biomarker assays for tissue phenotyping and digital pathology, has appointed Mike Sismour as vice president, research, and Mark Rees as vice president, corporate development.

Sismour most recently served as chief scientist/head of genomics R&D at Beckman Coulter Life Science. He was a National Institutes of Health Ruth L. Kirschstein postdoc at Harvard Medical School and a fellow at Harvard's Wyss Institute.

Rees most recently worked for StatLab where he helped create a diagnostic division. He previously held leadership roles in commercial development, scientific affairs, and R&D at Enzo Life Sciences, Leica Biosystems (Danaher), and Novocastra Laboratories.

Feb 23, 2021

908 Devices: Jeff George, Fenel Eloi

Mass spectrometry firm 908 Devices has appointed Jeff George and Fenel Eloi to its board of directors.

George has previously served as the global division head and CEO of two divisions of Novartis, Sandoz, and Alcon from 2008 to 2016. In parallel, he served on the Novartis Group executive committee. He also serves on the board of directors of Amneal Pharmaceutical, Dorian Therapeutics, and Wishbone Medical.

Eloi previously served as CFO then COO at Cell Signaling Technology. He also serves on the board of directors of MitoTherapeutix.

Feb 23, 2021

ImmunoScape: Geoff Nosrati

Singapore-based immune profiling company ImmunoScape has named Geoff Nosrati as chief business officer in conjunction with the establishment of the firm's US headquarters in San Diego. Before joining ImmunoScape, Nosrati advised biotechnology clients at McKinsey & Co. He also held senior executive positions at Aduro Biotech. Nosrati holds a PhD in biochemistry and molecular biology from the University of California, Los Angeles.

Feb 23, 2021

Qiagen: Thomas Ebeling

Thoms Ebeling has been appointed to Qiagen's supervisory board. Ebeling has been an advisor in recent years to various companies after having served as CEO of German media group ProSiebenSat.1 from 2009 to 2018. Prior to that he worked for Novartis from 1997 to 2008, including as CEO of Novartis Pharmaceuticals and CEO of Novartis Consumer Health. Ebeling has also previously served on the supervisory boards of Bayer and Lonza.

In a letter, about two dozen researchers criticize the World Health Organization investigation into the origins of SARS-CoV-2 and call for a new inquiry, the Wall Street Journal reports.

National Geographic reports that nine great apes at the San Diego Zoo have been vaccinated against SARS-CoV-2.

Janet Woodcock, the acting commissioner of the US Food and Drug Administration, speaks with NPR about SARS-CoV-2 testing and vaccines in the US.

In Science this week: genetic study of kidney fibrosis implicates the SOX9-NAV3-YAP1 axis.